Controlled delivery of antisense oligonucleotides: A brief review of current strategies

Expert Opinion on Drug Delivery

Volumn 6, Issue 7, 2009, Pages 673-686

  Zhao, Xiubo ^a   Pan, Fang ^a   Holt, Cathy M ^a   Lewis, Andrew L ^b   Lu, Jian R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

Antisense; Cationic lipids; Controlled release; Gene delivery; Liposomes; Microspheres; Nanoparticles; Oligonucleotides; Polymers; Surface matrices

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,2 DIOLEOYLGLYCERO 3 PHOSPHATIDYLETHANOLAMINE; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; CARBON NANOTUBE; CETRIMIDE; CHOLESTEROL; COPOLYMER; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DIMYRISTOOXYPROPYLDIMETHYLHYDROXYETHYLAMMONIUM BROMIDE; GOLD NANOPARTICLE; LIPID; LIPOFECTIN; LIPOPLEX; LIPOSOME; MACROGOL DERIVATIVE; MESSENGER RNA; MICROSPHERE; NANOPARTICLE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGOFECTAMINE; PEPTIDE; PEPTIDE NUCLEIC ACID; POLOXAMER; POLYETHYLENEIMINE; POLYMER; POLYPLEX; POLYSACCHARIDE; SURFACTANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTISENSE THERAPY; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; GENE EXPRESSION REGULATION; HUMAN; HYDROGEL; LIPOSOMAL GENE DELIVERY SYSTEM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; SURFACE PROPERTY;

ANIMALS; DELAYED-ACTION PREPARATIONS; GENE TARGETING; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIPIDS; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDES; POLYMERS; RNA, MESSENGER;

EID: 67650403364     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240902992894     Document Type: Review

References (121)

1. Crooke ST. Progress in antisense technology. Annu Rev Med 2004;55:61-95 •• A comprehensive review of antisense technology.
2. Sepp-Lorenzino L, Ruddy M. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin Pharmacol Ther 2008;84:628-632
3. Aboul-Fadl T. Antisense oligonucleotide technologies in drug discovery. Expert Opin Drug Discov 2006;1:285-288
4. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-284 (Pubitemid 8290783)
5. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978;75:285-288 (Pubitemid 8290784)
6. Toub N, Malvy C, Fattal E, Couvreur P. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother 2006;60:607-620
7. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347-355
8. Hughes MD, Hussain M, Nawaz Q, et al. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001;6:303-315 (Pubitemid 32194667)
9. Isaka Y, Imai E, Takahara S, Rakugi H. Oligonucleotidic therapeutics. Expert Opin Drug Discov 2008;3:991-996
10. Sundaram S, Viriyayuthakorn S, Roth CM. Oligonucleotide structure influences the interactions between cationic polymers and oligonucleotides. Biomacromolecules 2005;6:2961-2968 (Pubitemid 41764050)
11. Eckstein F. The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther 2007;7:1021-1034
12. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 1988;85:5011-5015
13. Read ML, Bremner KH. Antisense strategies and non-viral gene therapy for cancer. Expert Opin Ther Patents 2002;12:379-391 (Pubitemid 34223898)
14. De-Rosa G, Quaglia F, Bochot A, et al. Long-term release and improved intracellular penetration of oligonucleotide-polyethylenimine complexes entrapped in biodegradable microspheres. Biomacromolecules 2003;4:529-36 •• This paper reports the use of microspheres for antisense oligonucleotide delivery.
15. Lee LK, Williams CL, Devore D, Roth CM. Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides. Biomacromolecules 2006;7:1502-1508 (Pubitemid 43811206)
16. Malik R, Roy L. Design and development of antisense drugs. Expert Opin Drug Discov 2008;3:1189-1207
17. Wang L, Kristensen J, Ruffner DE. Delivery of antisense oligonucleotides using HPMA polymer: synthesis of a thiol polymer and its conjugation to water-soluble molecules. Bioconjug Chem 1998;9:749-757
18. Leaman DW. Recent progress in oligonucleotide therapeutics: antisense to aptamers. Expert Opin Drug Discov 2008;3:997-1009
19. Opalinska J. Nucleic acid drugs in the clinic. Expert Opin Drug Discov 2007;2:321-333
20. Vasir JK, Labhasetwar V. Polymeric nanoparticles for gene delivery. Expert Opin Drug Deliv 2006;3:325-344
21. Segura T, Shea LD. Materials for non-viral gene delivery. Annu Rev Mater Res 2001;31:25-46 • This paper reviews the materials that have been used for non-viral gene delivery.
22. Good L. Antisense antibacterials. Expert Opin Ther Patents 2002;12:1173-1179
23. El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004;94:1-14 (Pubitemid 37542373)
24. Karinaga R, Anada T, Minari J, et al. Galactose-PEG dual conjugation of b-(1-3)-D-glucan schizophyllan for antisense oligonucleotides delivery to enhance the cellular uptake. Biomaterials 2006;27:1626-1635
25. Zuhorn IS, Engberts JBFN, Hoekstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 2007;36:349-62 • This paper reviews the cationic lipids for gene delivery.
26. Chirila TV, Rakoczy PE, Garrett KL, et al. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 2002;23:321-342 (Pubitemid 33051022)
27. Goyal P, Goyal K, Kumar SGV, et al. Liposomal drug delivery systems - clinical applications. Acta Pharm 2005;55:1-25 (Pubitemid 40562616)
28. Christian DA, Cai S, Bowen DM, et al. Polymersome carriers: from self-assembly to siRNA and protein therapeutics. Eur J Pharm Biopharm 2009;71:463-474
29. Garcia-Chaumont C, Seksek O, Grzybowska J, et al. Delivery systems for antisense oligonucleotides. Pharmacol Ther 2000;87:255-277
30. Abes S, Williams D, Prevot P, et al. Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J Control Release 2006;2006:595-604 (Pubitemid 43163449)
31. Horwich MD, Zamore PD. Design and delivery of antisense oligonucleotides to block microRNA function in cultured Drosophila and human cells. Nat Protocols 2008;3:1537-1549
32. Rayburn ER, Wang H, Zhang R. Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs 2006;11:337-352
33. Chiarantini L, Ceras A, Fraternale A, et al. Comparison of novel delivery systems for antisense peptide nucleic acids. J Control Release 2005;109:24-36 (Pubitemid 41737250)
34. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008;36:4158-4171 (Pubitemid 351984831)
35. Shi F, Hoekstra D. Effective intracellular delivery of oligonucleotides in order to make sense of antisense. J Control Release 2004;97:189-209 (Pubitemid 38759477)
36. Godfray J, Estibeiro P. The potential of antisense as a CNS therapeutic. Expert Opin Ther Targets 2003;7:363-376
37. Veldhoen S, Laufer SD, Restle T. Recent developments in peptide-based nucleic acid delivery. Int J Mol Sci 2008;9:1276-1320
38. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. CMLS Cell Mol Life Sci 2005;62:1839-1849 (Pubitemid 41188523)
39. Maier MA, Esau CC, Siwkowski AM, et al. Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids. J Med Chem 2006;49:2534-2542
40. Bayele HK, Sakthivel T, O'Donell M, et al. Versatile peptide dendrimers for nucleic acid delivery. J Pharm Sci 2005;94:446-457 (Pubitemid 40293339)
41. Martin VL, Roy S, Armitage BA. Recent advances in the development of peptide nucleic acid as gene-targeted drug. Expert Opin Biol Ther 2004;4:337-348 (Pubitemid 38352130)
42. Kichler A. Gene transfer with modified polyethylenimines. J Gene Med 2004;6:S3-10
43. Jia N, Lian Q, Shen H, et al. Intracellular delivery of quantum dots tagged antisense oligodeoxynucleotides by functionalized multiwalled carbon nanotubes. Nano Lett 2007;7:2976-2980
44. Gao S, Chen J, Dong L, etal. Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector. Eur J Pharm Biopharm 2005;60:327-334 (Pubitemid 40922830)
45. Hadaschik BA, Jackson J, Fazli L, et al. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. BJU Int 2008;102:610-616
46. Mehier-Humbert S, Guy RH. Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev 2005;57:733-753 (Pubitemid 40332600)
47. Zhao X, Pan F, Zhang Z, et al. Nanostructure of polyplexes formed between cationic diblock copolymer and antisense oligodeoxynucleotide and its influence on cell transfection efficiency. Biomacromolecules 2007;8:3493-502 •• This paper investigates the nanostructure of the ODN/polymer complexes and their transfection.
48. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7417
49. Zhang S, Xu Y, Wang B, et al. Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release 2004;100:165-80 • This paper reviews the cationic compounds for gene delivery.
50. Rao NM, Gopal V. Cationic lipids for gene delivery invitro and invivo. Expert Opin Ther Patents 2006;16:825-844 (Pubitemid 43949965)
51. Lindner LH, Brock R, Arndt-Jovin D, Eibl H. Structural variation of cationic lipids: Minimum requirement for improved oligonucleotide delivery into cells. J Control Release 2006;110:444-456 (Pubitemid 41827499)
52. Farhood H, Serbina S, Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta 1995;1235:289-295
53. Yamauchi M, Kusano H, Saito E, et al. Improved formulations of antisense oligodeoxynucleotides using wrapped liposomes. J Control Release 2006;114:268-275 (Pubitemid 44291849)
54. Pakunlu RI, Wang Y, Saad M, etal. Invitro and invivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006;114:153-162 (Pubitemid 44291853)
55. Wong FMP, Macadam SA, Kim A, et al. A lipid-based delivery system for antisense oligonucleotides derived from a hydrophobic complex. J Drug Target 2002;10:615-623 (Pubitemid 36124362)
56. Wilson A, Zhou W, Champion HC, et al. Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells invitro and in vivo. Mol Ther 2005;12:510-518 (Pubitemid 41150137)
57. Chiu S-J, Liu S, Perrotti D, et al. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release 2006;112:199-207
58. Zhang Y, Qi XR, Gao Y, etal. Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J Control Release 2007;117:281-290 (Pubitemid 46161882)
59. Lv H, Zhang S, Wang B, etal. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114:100-109 (Pubitemid 44128621)
60. Weyermann J, Lochmann D, Zimmer A. Comparison of antisense oligonucleotide drug delivery systems. J Control Release 2004;100:411-423 (Pubitemid 39572921)
61. Zhao X, Zhang Z, Pan F, et al. Plasmid DNA complexation with phosphorylcholine diblock copolymers and its effect on cell transfection. Langmuir 2008;24:6881-8 • This paper investigates the nanostructure of the plasmid/polymer complexes and their transfection.
62. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002;54:715-758 (Pubitemid 35247524)
63. Neu M, Fischer D, Kissel T. Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J Gene Med 2005;7:992-1009 (Pubitemid 41195062)
64. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and developement of polymers for gene delivery. Nat Rev Drug Discov 2005;4:581-93 •• This paper reviews the polymer-based gene delivery.
65. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Control Release 1999;60:149-160 (Pubitemid 29335941)
66. Dufès C, Uchegbu IF, Schätzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005;57:2177-2202
67. Nam HY, Hahn HJ, Nam K, et al. Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery. Int J Pharm 2008;363:199-205
68. Zhao XB, Lee RJ. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev 2004;56:1193-1204 (Pubitemid 38496515)
69. Sarkar T, Conwell CC, Harvey LC, et al. Condensation of oligonucleotides assembled into nicked and gapped duplexes: potential structures for oligonucleotide delivery. Nucleic Acids Res 2005;33:143-151 (Pubitemid 40276936)
70. Zhu J, Tang A, Law LP, et al. Amphiphilic core-shell nanoparticles with poly(ethylenimine) shells as potential gene delivery carriers. Bioconjug Chem 2005;16:139-146
71. Carlisle RC, Etrych T, Briggs SS, et al. Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction. J Gene Med 2004;6:337-344 (Pubitemid 40228051)
72. Dailey LA, Kleemann E, Merdan T, et al. Modified polyethylenimines as non viral gene delivery systems for aerosol therapy: effects of nebulization on cellular uptake and transfection efficiency. J Control Release 2004;100:425-436 (Pubitemid 39572922)
73. Williams JH, Schray RC, Sirsi SR, Lutz GJ. Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice. BMC Biotechnol 2008;8:35 (Pubitemid 351619156)
74. Sirsi SR, Williams JH, Lutz GJ. Poly(ethylene imine)-poly(ethylene glycol) copolymers facilitate efficient delivery of antisense oligonucleotides to nuclei of mature muscle cells of mdx mice. Hum Gene Ther 2005;16:1307-1317 (Pubitemid 41611658)
75. Kim SH, Mok H, Jeong JH, et al. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug Chem 2006;17:241-244 (Pubitemid 43157607)
76. Vinogradov SV, Batrakova EV, Li S, Kabanov AV. Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides. J Drug Target 2004;12:517-526 (Pubitemid 40081306)
77. Glodde M, Sirsi SR, Lutz GJ. Physiochemical properties of low and high molecular weight poly(ethylene glycol)-grafted poly(ethylene imine) copolymers and their complexes with oligonucleotides. Biomacromolecules 2006;7:347-56 • This paper investigates how the molecular masses of the polymers affect the gene delivery.
78. Lomas H, Marzia Massignani, Abdullah KA, et al. Non-cytotoxic polymer vesicles for rapid and efficient intracellular delivery. Faraday Discuss 2008;139:143-159
79. Lomas H, Canton I, MacNeil S, et al. Biomimetic pH sensitive polymersomes for efficient DNA encapsulation and delivery. Adv Mater 2007;19:4238-4243 (Pubitemid 350254804)
80. Nafee N, Taetz S, Schneider M, et al. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 2007;3:173-183 (Pubitemid 47332344)
81. Pan B, Cui D, Sheng Y, et al. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res 2007;67:8156-8163 (Pubitemid 47395151)
82. Wernig K, Griesbacher M, Andreae F, et al. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. J Control Release 2008;130:192-198
83. Tahara K, Sakai T, Yamamoto H, et al. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int J Pharm 2008;354:210-216
84. Giljohann DA, Seferos DS, Patel PC, et al. Oligonucleotide loading determines cellular uptake of DNA-modified gold nanoparticles. Nano Lett 2007;7:3818-3821
85. Rosi NL, Giljohann DA, Thaxton CS, et al. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006;312:1027-1030 (Pubitemid 43752907)
86. Patel PC, Giljohann DA, Seferos DS, Mirkin CA. Peptide antisense nanoparticles. Proc Natl Acad Sci USA 2008;105:17222-17226
87. Zhu S-G, Xiang J-J, Li X-L, et al. Poly(L-lysine)-modified silica nanoparticles for the delivery of antisense oligonucleotides. Biotechnol Appl Biochem 2004;39:179-187 (Pubitemid 38510063)
88. Wartlick H, Spänkuch-Schmitt B, Strebhardt K, etal. Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles. J Control Release 2004;96:483-495 (Pubitemid 38553926)
89. Steinhauser IM, Langer K, Strebhardt KM, Spänkuch B. Effect of trastuzumab modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. Biomaterials 2008;29:4022-4028
90. Santos ALGD, Bochot A, Doyle A, et al. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-β2 oligonucleotide improves the outcome of glaucoma surgery. J Control Release 2006;112:369-381 (Pubitemid 43737146)
91. Kovacs JR, Zheng Y, Shen H, Meng WS. Polymeric microspheres as stabilizing anchors for oligonucleotide delivery to dendritic cells. Biomaterials 2005;26:6754-6761 (Pubitemid 41021768)
92. Akhtar S, Lewis KJ. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres. Int J Pharm 1997;151:57-67 (Pubitemid 27212304)
93. Phull H, Lien Y-HH, Salkini MW, et al. Delivery of intercellular adhesion molecule-1 antisense oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy/ischemia model. Urology 2008;72:690-695
94. Vinogradov SV, Batrakova EV, Kabanov AV. Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 2004;15:50-60
95. Khan A, Sommer W, Fuxe K, Akhtar S. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain. J Drug Target 2000;8:319-334 (Pubitemid 32186101)
96. Nyce JW. Antisense oligonucleotides: local delivery enhances their therapeutic potential. Expert Opin Ther Patents 1999;9:263-267 (Pubitemid 29108119)
97. Takahashi H, Letourneur D, Grainger DW. Delivery of large biopharmaceuticals from cardiovascular stents: a review. Biomacromolecules 2007;8:3281-93 • This paper reviews the controlled release of large molecules from cardiovascular stents.
98. Zhang Z, Cao X, Zhao X, et al. Controlled delivery of antisense oligodeoxynucleotide from cationically modified phosphorylcholine polymer films. Biomacromolecules 2006;7:784-91 •• This paper investigates the controlled release of AS-ODN from single-layer polymer film.
99. Zhang Z, Cao X, Zhao X, et al. Controlled delivery of anti-sense oligodeoxynucleotide from multilayered biocompatible phosphorylcholine polymer films. J Control Release 2008;130:69-76 •• This paper investigates the controlled release of AS-ODN from multilayered polymer films.
100. Lewis AL. Phosphorylcholine-based polymers and their use in the prevention of biofouling. Colloids Surf B Biointerfaces 2000;18:261-275 (Pubitemid 30479867)
101. Lewis AL, Freeman RNT, Redman RP, et al. Wettable phosphorylcholine- containing polymers useful in blood filtration. J Mater Sci Mater Med 2003;14:39-45 (Pubitemid 36241295)
102. Lewis AL, Hughes PD, Kirkwood LC, et al. Synthesis and characterisation of phosphorylcholine-based polymers useful for coating blood filtration devices. Biomaterials 2000;21:1847-1859 (Pubitemid 30398503)
103. Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphorylcholine- based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 2002;23:1697-1706 (Pubitemid 34158593)
104. Willis SL, Court JL, Redman RP, et al. A novel phosphorylcholine-coated contact lens for extended wear use. Biomaterials 2001;22:3261-3272 (Pubitemid 32926710)
105. Rose SF, Lewis AL, Hanlon GW, Lloyd AW. Biological responses to cationically charged phosphorylcholine-based materials in vitro. Biomaterials 2004;25:5125-5135 (Pubitemid 38510398)
106. Zhao X, Pan F, Coffey P, Lu JR. Cationic copolymer-mediated DNA immobilization: interfacial structure and composition as determined by ellipsometry, dual polarization interferometry, and neutron reflection. Langmuir 2008;24:13556-13564
107. Zhao X, Zhang Z, Pan F, et al. Solution pH regulated interfacial adsorption of diblock phosphorylcholine copolymers. Langmuir 2005;21:9597-9603 (Pubitemid 41507012)
108. Zhao X, Zhang Z, Pan F, et al. DNA immobilization using biocompatible diblock phosphorylcholine copolymers. Surf Interface Anal 2006;38:548-551
109. Chim YTA, Lam JKW, Ma Y, et al. Structural study of DNA condensation induced by novel phosphorylcholine-based copolymers for gene delivery and relevance to DNA protection. Langmuir 2005;21:3591-3598 (Pubitemid 40538371)
110. Lam JKW, Ma Y, Armes SP, et al. Phosphorylcholine-polycation diblock copolymers as synthetic vectors for gene delivery. J Control Release 2004;100:293-312 (Pubitemid 39491280)
111. Salvage JP, Rose SF, Phillips GJ, et al. Novel biocompatible phosphorylcholine-based self-assembled nanoparticles for drug delivery. J Control Release 2005;104:259-270 (Pubitemid 40724928)
112. Palmer RR, Lewis AL, Kirkwood LC, et al. Biological evaluation and drug delivery application of cationically modified phospholipid polymers. Biomaterials 2004;25:4785-4796 (Pubitemid 38561166)
113. Xu J-P, Ji J, Chen W-D, Shen J-C. Novel biomimetic polymersomes as polymer therapeutics for drug delivery. J Control Release 2005;107:502-512 (Pubitemid 41393357)
114. Giacomelli C, Men LL, Borsali R, et al. Phosphorylcholine-based pH-responsive diblock copolymer micelles as drug delivery vehicles: light scattering, electron microscopy, and fluorescence experiments. Biomacromolecules 2006;7:817-828
115. Lewis AL, Vick TA, Collias ACM, et al. phosphorylcholine-based polymer coatings for stent drug delivery. J Mater Sci Mater Med 2001;12:865-870 (Pubitemid 34062103)
116. Lewis AL, Furze JD, Small S, et al. Long-term stability of a coronary stent coating post-implantation. J Biomed Mater Res (Appl Biomater) 2002;63:699-705 (Pubitemid 35375415)
117. Zhao X, Pan F, Lu JR. Interfacial immobilization of DNA molecules. Annu Rep Prog Chem Sect C Phys Chem 2007;103:261-286
118. Chan KH, Armstrong J, Withers S, et al. Vascular delivery of c-myc antisense from cationically modified phosphorylcholine coated stents. Biomaterials 2007;28:1218-1224 (Pubitemid 44816381)
119. Lewis A, Berwick J, Davies MC, et al. Synthesis and characterisation of cationically modified phospholipid polymers. Biomaterials 2004;25:3099-3108 (Pubitemid 38210202)
120. Branco MC, Schneider JP. Self-assembling materials for therapeutic delivery. Acta Biomaterialia 2009;5:817-831
121. Nagai Y, Unsworth LD, Koutsopoulos S, Zhang S. Slow release of molecules in self-assembling peptide nanofiber scaffold. J Control Release 2006;115:18-25 (Pubitemid 44415076)